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Background
Additional information on the outcomes of patients with
AIDS-related Kaposi’ss a r c o m a( A I D S - K S )o nh i g h l y
active antiretroviral therapy (HAART) in resource-lim-
ited settings is needed. This study evaluated outcomes
in AIDS-KS patients after initiation of HAART in
Zimbabwe.
Methods
A retrospective cohort of 124 patients from the Parire-
nyatwa Hospital Kaposi’s Sarcoma and Opportunistic
Infections (OI) Clinics was studied. 31 patients with
AIDS-KS were matched 1:3 to 93 non-KS AIDS patients
based on date of initiation of HAART, gender, and age.
The primary endpoint was loss to care, defined as failure
to attend clinic or refill prescriptions for 3 months or
longer. Secondary endpoints were weight gain at
6 months, change in CD4+ count within 1 year, and
f i n a lC D 4 +c o u n tw i t h i n1y e a ro fi n i t i a t i n gH A A R T .
Eligibility criteria included a minimum of 6 months of
followup in the OI Clinic and less than 2 months of pre-
vious HAART prior to beginning therapy through the
OI Clinic. A two-step model-selection strategy using KS
status, gender, age, WHO performance status, OI dis-
ease burden, medical aid, employment, education, pre-
treatment cotrimoxazole use, pre-treatment weight, and
pre-treatment CD4+ count was used to identify factors
associated with loss to care. On the initial univariate
analysis, KS status, medical aid, and pre-treatment cotri-
moxazole use had a p<0.15 and were included in the
final multivariate analysis.
Results
AIDS-KS and non-KS patients did not differ significantly
in baseline characteristics except for pre-treatment
CD4+ count (196 vs. 92 cells/mm
3, p=0.005). On the
multivariate analysis, KS status (p=0.016, HR: 4.11, CI:
1.31-12.92) and having medical aid were significant pre-
dictors of loss to care (p=0.048, HR: 3.84, CI: 1.02-
14.44). At a median followup of 632 days, 37.5% of
AIDS-KS patients were lost to care compared to 16.1%
of non-KS patients. AIDS-KS patients had significantly
worse weight gain than non-KS patients (+0.78%
vs. +4.18%, p=0.023). Change in CD4+ count (p=0.149)
and final CD4+ count (p=0.729) were not significantly
different between study groups. Amongst AIDS-KS
patients, retained patients (n=20) had significantly
higher pre-treatment CD4+ counts than patients lost to
care (n=11) (232 vs. 122 cells/mm
3, p=0.048).
Conclusions
After initiating HAART, AIDS-KS patients experienced
greater loss to care and poorer weight gain than
matched non-KS patients, suggesting that, under routine
conditions in Zimbabwe, AIDS-KS patients have worse
intermediate- and long-term clinical outcomes than
non-KS AIDS patients. AIDS-KS patients retained in
care had higher pre-treatment CD4+ counts than
patients lost to care, indicating that early intervention
with HAART may improve outcomes in AIDS-KS
patients.
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